Patients with Type 2 Diabetes Mellitus (T2DM):
VILDAMET is indicated as an adjunct to diet and exercise in patients whose glycemic control is inadequate with metformin hydrochloride or vildagliptin monotherapy, or in patients already treated with a free combination of metformin hydrochloride and vildagliptin.
VILDAMET is indicated in combination with a sulfonylurea (i.e., as triple therapy) as an adjunct to diet and exercise in patients insufficiently controlled with metformin and a sulfonylurea.
VILDAMET is indicated in combination with insulin to improve glycemic control in patients who are inadequately controlled with diet, exercise, and a stable dose of insulin plus metformin.
| Specialty | VILDAMET |
|---|---|
| Dosage | 1000 mg, 50 mg |
| Form | Film-coated tablet |
| Presentation | B/30 |
| Primary Packaging | Blister |
| Specification | ALU |
| INN | VILDAGLIPTIN + METFORMIN |
| VEIC Classification | Essential |
| Therapeutic Class | DIGESTIVE SYSTEM AND METABOLISM |
| Subclass | MEDICINAL PRODUCT USED IN THE TREATMENT OF DIABETES |
| Laboratory | PHILADELPHIA PHARMA |
| Schedule | A |
| Shelf Life | 18 (months) |
| Generic/Brand | Generic |
| MA Number | 9353281 |
Reviews
There are no reviews yet.